4D Presents Phase Ib Clinical Data on ThetanixR

– The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 adolescent patients with Crohn’s disease. In the single-dose phase, eight subjects were given a single dose of either ThetanixR or placebo. In the multiple-dose phase, 10 subjects were given either ThetanixR or placebo twice daily for seven consecutive days.

This study met its primary objective, demonstrating that ThetanixR was well tolerated with a good safety profile.

The Lead Investigator Richard Hansen, Consultant Paediatric Gastroenterologist, Royal Hospital for Children, Glasgow will also give an oral presentation on this data at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) in Glasgow, UK, on 7 June 2019.The poster and presentation from these meetings will be made available on the 4D website in due course.

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRxR, that rationally identifies novel bacteria based on a deep understanding of function and mechanism.  4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of BlautixR in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KeytrudaR in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.

About Crohn’s Disease

Crohn’s disease is a chronic inflammatory bowel disease which can occur in any part of the gastro-intestinal tract, but primarily affects the small intestine. Patients suffer from diarrhoea, rectal bleeding and abdominal pain. Many often require long-term medical therapy, are repeatedly hospitalised and may even require surgical intervention. Crohn’s disease remains an area of significant unmet medical need. In the mild-to-moderate population, patients are typically treated with long-term immunosuppressants, which are not effective in all individuals and often lead to the development of severe side effects. Safe and effective novel drugs are needed to provide improved treatment options for patients, particularly in the maintenance therapy setting. The global market for Crohn’s disease was worth $10.4 billion in 2017 and is expected to grow to approximately $11.5 billion by 2024.

Paediatric CD is a severe condition with additional health impacts such as impaired development and growth retardation. The frequency of extensive disease with more severe lower bowel involvement is much more common in the paediatric population than in adults. Immunomodulators, biologics and steroids, whilst used widely to treat the adult population are often considered too aggressive for use in children and there is a clear unmet need for safe and effective long-term alternatives to these products.

About ThetanixR

ThetanixR is a single-strain Live Biotherapeutic candidate in development for the treatment of Crohn’s disease. It acts upstream of many biologics that are approved for Crohn’s disease and inhibits NF-κB activation which has been found to be overactive in many inflammatory diseases. A pirin-like protein (PLP) produced by the bacteria has been identified as a candidate effector molecule. In addition to showing efficacy in multiple preclinical models of Inflammatory Bowel Disease, the Phase Ib study demonstrated safety and tolerability and a Phase II study is being planned. ThetanixR has orphan drug designation for paediatric Crohn’s disease.

For further information please contact 4D:

Duncan PeytonChief Executive Officer+44 (0)113-895-0130

Fay WestonHead of Investor Relations+44 (0)7990-381713

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)